Literature DB >> 2184004

Chemotherapy for prostate cancer. Present concerns and future considerations.

G D Chisholm1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2184004     DOI: 10.2165/00003495-199039030-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  11 in total

Review 1.  A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.

Authors:  M A Eisenberger; R Simon; P J O'Dwyer; R E Wittes; M A Friedman
Journal:  J Clin Oncol       Date:  1985-06       Impact factor: 44.544

Review 2.  Chemotherapy for prostatic carcinoma.

Authors:  M A Eisenberger; J S Abrams
Journal:  Semin Urol       Date:  1988-11

3.  Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation.

Authors:  D Hickey; J Cant; M S Soloway
Journal:  Urology       Date:  1988-01       Impact factor: 2.649

Review 4.  Treatment of advanced cancer of the prostate.

Authors:  G D Chisholm
Journal:  Semin Surg Oncol       Date:  1985

5.  Orchiectomy and chemotherapy with estramustine, cis-platinum, cyclophosphamide, and 5-fluorouracil in newly diagnosed prostate cancer with bone metastases.

Authors:  S Eisenkraft; R P Huben; J E Pontes
Journal:  Urology       Date:  1984-06       Impact factor: 2.649

6.  Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

Authors:  I F Tannock
Journal:  J Clin Oncol       Date:  1985-07       Impact factor: 44.544

7.  The stable state is not an objective response in hormone-escaped carcinoma of prostate.

Authors:  L L Beynon; G D Chisholm
Journal:  Br J Urol       Date:  1984-12

8.  The treatment of oestrogen-escaped carcinoma of the prostate with estramustine phosphate.

Authors:  G D Chisholm; E P O'Donoghue; C L Kennedy
Journal:  Br J Urol       Date:  1977

9.  Combined hormone-chemotherapy for metastatic prostatic carcinoma. Eleven-year follow-up.

Authors:  C Servadio; M Savion; E Mukamel
Journal:  Urology       Date:  1987-10       Impact factor: 2.649

10.  Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial.

Authors:  G P Murphy; R L Priore; P T Scardino
Journal:  Urology       Date:  1988-07       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.